Method of Ameliorating Clotting Pathologies and Related Materials and Methods

Patent metadata

Field	Value
Publication number	US-2017333389-A1
Application number	US-201715653863-A
Country	US
Kind code	A1
Filing date	Jul 19, 2017
Priority date	Jul 19, 2012
Publication date	Nov 23, 2017
Grant date	—

Abstract

Methods for reducing blood clotting in a subject are provided, including methods to reduce the risk of and/or treat blot clotting pathologies. Also provided are compositions useful to reduce the risk or treat blood clotting pathologies.

First claim

What is claimed is:

1 . A method of reducing blood clotting in a stroke survivor subject in need thereof, comprising:
administering a pharmaceutically-effective formulation of a tocotrienol-containing composition, and, administering pharmaceutically-effective formulation of clopigrel, and optionally, administering pharmaceutically-effective formulation of aspirin, sufficient to reduce risk of a further stroke in the subject.

2 . The method of claim 1 , wherein the tocotrienol-containing composition comprises: d-alpha-tocotrienol, d-gamma-tocotrienol, and d-delta-tocotrienol.

3 . The method of claim 1 , wherein the tocotrienol-containing composition comprises: d-alpha-tocotrienol, d-gamma-tocotrienol, d-delta-tocotrienol, and d-alpha-tocopherol.

4 . The method of claim 1 , wherein the tocotrienol-containing composition comprises: d-alpha-tocotrienol 61.52 mg, d-gamma-tocotrienol 112.80 mg, d-delta-tocotrienol 25.68 mg, d-alpha-tocopherol 91.60 IU, plant squalene 51.28 mg, phytosterol complex 20.48 mg, and phytocarotenoid complex 360.00 ug.

5 . A method of claim 1 , which comprises administering up to 400 mg of the tocotrienol-containing composition for at least 30 days, and a pharmaceutically-effective dose of the tocotrienol-containing composition weekly thereafter.

6 . The method of claim 1 , wherein the formulation comprises a dose of the tocotrienol-containing composition selected from the group consisting of: approximately 200 mg to approximately 1000 mg in one weekly dose; approximately 300 mg to approximately 1000 mg in one weekly dose; approximately 400 mg to approximately 500 mg in one weekly dose.

7 . The method of claim 1 , wherein the tocotrienol-containing composition is an orally-delivered supplement.

8 . A method of reducing blood clotting in a subject in need thereof, comprising administering a pharmaceutically-effective formulation of at least one isoform of a tocotrienol and reducing blood clotting in a subject.

9 . The method of claim 8 , wherein the formulation comprises a dose of tocotrienol selected from the group consisting of: approximately 10 mg to approximately 1000 mg per day;
approximately 50 mg to approximately 500 mg per day; approximately 100 mg to approximately 500 mg per day; approximately 200 mg to approximately 500 mg per day; approximately 300 mg to approximately 500 mg per day; up to approximately 400 mg per day.

10 . The method of claim 8 , wherein the formulation comprises a dose of tocotrienol selected from the group consisting of: approximately 200 mg to approximately 1000 mg in one weekly dose; approximately 300 mg to approximately 1000 mg in one weekly dose; approximately 400 mg to approximately 500 mg in one weekly dose.

11 . The method of claim 8 , wherein the formulation is administered as a dose regimen selected from the group consisting of: approximately every other day; approximately every third day; approximately every fourth day; approximately every fifth day; approximately every sixth day; approximately every seventh day; approximately every other week; approximately once a month; approximately twice a month; approximately three times a month; approximately four times a month; approximately five times a month; approximately six times a month; approximately seven times a month; and approximately eight times a month.

12 . The method of claim 8 , wherein the formulation is an orally-delivered supplement.

13 . The method of claim 12 , wherein the oral supplement is delivered by one or more of: a capsule, a tablet pill, a colloid, a piece of chewing gum, a gel, a drink, a food additive, a thin film dissolving strip, an emulsified food spread, an emulsion, a syrup, a meat food, a dairy food, and an egg.

14 . The method of claim 8 , wherein the subject is selected from a population at elevated risk for a blood clotting pathology selected from the group consisting of: transient ischemic attack (TIA); stroke; embolism; and cardiac arrest.

15 . The method of claim 8 , wherein the subject is selected from the group consisting of: wherein the subject is selected from: a person who has suffered a previous blood clotting pathology; a person who has suffered a stroke; a person who has suffered a cardiac event; a person who has suffered from transient ischemic attack; a person who has suffered an embolism; a person who has suffered a thrombosis; a person with a genetic predisposition for pathologic blood clotting; a person with biomarkers for pathologic blood clotting; and a person who takes anticoagulants.

16 . A method of reducing risk of a second stroke in a stroke patient in need thereof, comprising administering a pharmaceutically-effective formulation of at least one isoform of a tocotrienol and reducing risk of a second stroke in a stroke patient in need thereof.

17 . A method of claim 16 , which further comprises administering to the patient a pharmaceutically-effective amount of clopidogrel.

18 . A method of claim 16 , which comprises administering up to 400 mg of at least one tocotrienol for at least 30 days, and a pharmaceutically-effective dose of at least one tocotrienol weekly thereafter.

Assignees

• Univ Ohio State

Inventors

• Sen Chandan K
• Rink Cameron
• Roy Sashwati
• Khanna Savita

Classifications

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A23L15/00 Primary

  Egg products; Preparation or treatment thereof · CPC title

• A61K31/616

  by carboxylic acids, e.g. acetylsalicylic acid · CPC title

• A23K50/40

  for carnivorous animals, e.g. cats or dogs · CPC title